title: [Impact of recombinant human thrombopoietin (rhTPO) on short-term response of immunosuppressive therapy in patients with newly diagnosed acquired severe aplastic anemia].
abstract: OBJECTIVE
  To evaluate the impact of recombinant human thrombopoietin (rhTPO) on short-term response of immunosuppressive therapy (IST) in patients with newly diagnosed acquired severe aplastic anemia (SAA).
  
  
  METHODS
  The clinical data of forty adult acquired SAA patients, who treated with IST combined with rhTPO, were retrospective analyzed and the hematologic recovery were compared with patients by the IST alone during the same period. The factors affecting the short-term response were also analyzed.
  
  
  RESULTS
  At 3 months after IST, both the total response rate and CR+GPR rate in rhTPO group were much higher than those in control group (75.0% vs 50.0%, P=0.022; and 17.5% vs 2.5%, P=0.025). At 6 months after IST, there was no difference of total hematologic response rate in rhTPO group and control group (77.5% vs 57.5%, P=0.058), while the CR+GPR rate was still higher in rhTPO group (45.0% vs 22.5%, P=0.033). The median time of platelet transfusion independence was much shorter in rhTPO group [33(0-90) vs 53(0-75) d, P=0.019]. Patients in rhTPO group needed less platelets transfusion support. The median platelet count in rhTPO group was 29(4-95)×10⁹/L at 3 months after IST, which was much higher than that in control group [29(4-95)×10⁹/L, P=0.006]. There was no significant difference regarding overall survival between the two groups (100.0% vs 91.0%, P=0.276).
  
  
  CONCLUSIONS
  rhTPO is effective in promoting platelet recovery and improving the hematopoietic response for SAA patients with IST.
authors: Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
authors: Li
authors: L
authors: Zhang
authors: Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
authors: Wenrui
authors: W
authors: Yang
authors: Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
authors: Lei
authors: L
authors: Ye
authors: Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
authors: Kang
authors: K
authors: Zhou
authors: Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
authors: Liping
authors: L
authors: Jing
authors: Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
authors: Yang
authors: Y
authors: Li
authors: Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
authors: Yuan
authors: Y
authors: Li
authors: Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
authors: Jianping
authors: J
authors: Li
authors: Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
authors: Guangxin
authors: G
authors: Peng
authors: Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
authors: Lin
authors: L
authors: Song
authors: Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
authors: Xin
authors: X
authors: Zhao
authors: Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
authors: Zhijie
authors: Z
authors: Wu
authors: Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
authors: Fengkui
authors: F
authors: Zhang
mesh_terms: D000741:Anemia, Aplastic; D001792:Blood Platelets; D006801:Humans; D007165:Immunosuppression Therapy; D010976:Platelet Count; D017713:Platelet Transfusion; D011994:Recombinant Proteins; D012189:Retrospective Studies; D013926:Thrombopoietin
chemical_list: D011994:Recombinant Proteins; D013926:Thrombopoietin